Invited Oral Presentations in Pediatric Oncology

Monday, April 7, 2025, 9:00 AM - 10:00 AM

*All times are listed in Pacific Standard Time (PST; GMT -8:00)*

This session is available to Children's Oncology Group (COG) pharmacist members. Information about how to access the live stream will be provided by COG.

For information about claiming CE for this program please refer to the main webpage for this conference.

1. Review issues pertinent to oncology pharmacy practice
2. Recognize existing knowledge gaps and discuss directions for future research topics for the subjects discussed
3. Describe relevant clinical pearls relating to pediatric oncology pharmacy practice
4. Explain the role of the pharmacist as an active member of the clinical research team

Each session will have it's own title and objective(s) that will be provided once available.

The St. Jude Children’s Research Hospital Department of Pharmacy and Pharmaceutical Sciences is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.  

St. Jude Children’s Research Hospital designates this for a maximum of 1 CPE hours (0.1 CEU per 1 CPE hour).

Pharmacy continuing education credit will be available to all participants who attend, text attendance, and complete a program assessment and evaluation. Credits will be uploaded and viewable on-line at www.napb.net within approximately two weeks following the date of the presentation.  Participants should contact the CPE staff if credit does not appear within 4 weeks of a program.

 

ACPE - Accreditation Council for Pharmacy Education (1.00 hours), Non-Physician Attendance (1.00 hours)

Mitigation of Relevant Financial Relationships

St Jude Children's Research Hospital adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible entities (ie, companies whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Monday, April 7, 2025